BSX Unusual Options Activity — 2026-04-07

🏥 BSX $1.3M LEAPS Call Bet — Institutional Money Goes Long on Medtech's Growth Engine!

📅 April 7, 2026 | 🔥 Unusual Activity Detected

---

🎯 The Quick Take

Someone just dropped $1.3 MILLION into BSX March 2027 $70 calls — buying 2,000 LEAPS contracts nearly a year out on a strike sitting 13.9% above today's price. With an open interest of just 54 contracts before this trade, the Vol/OI ratio explodes to 37x — this is an unambiguously fresh, aggressive Buy-to-Open that dwarfs all prior positioning in this contract. The buyer is betting Boston Scientific rallies meaningfully from $61.44 toward and beyond $70 by March 2026 OPEX, powered by the medtech giant's durable revenue growth, margin expansion story, and a pipeline of structural heart and electrophysiology innovations. MID fill confirms institutional execution — not a retail market order.

---

📊 Company Overview

Boston Scientific (BSX) is one of the largest medical device companies in the world, building the tools that cardiologists, electrophysiologists, and interventional specialists rely on every day:

• 🩺 What they do: Designs, manufactures, and markets a broad spectrum of minimally-invasive medical devices across cardiovascular, rhythm management, endoscopy, neuromodulation, and urology
• 💰 Market Cap: ~$90B
• 🏢 Sector: Medical Devices & Instruments
• 📈 Exchange: NYSE
• 📊 Current Price: $61.44
• 💡 Key Story: BSX has compounded double-digit organic revenue growth over recent years, driven by WATCHMAN FLX (left atrial appendage closure), FARAPULSE pulsed field ablation (PFA), and a deep pipeline of structural heart and electrophysiology therapies that are still in early-to-mid adoption cycles globally

---

💰 The Option Flow Breakdown

📊 The Tape

🤓 What This Actually Means

Let me break this down in plain English:

• 💸 $1.3 million spent: 2,000 contracts at $6.60 each ($6.60 x 100 shares x 2,000 = ~$1.32M)
• 📈 Strike $70 is 13.9% above current price — solidly out-of-the-money, requiring a meaningful rally over 11 months
• ⏰ 346 days to expiration (March 19, 2027) — this is a true LEAPS play, giving the full medtech catalyst calendar time to develop
• 📊 Volume/OI ratio = 37x — volume (2,000) is thirty-seven times the prior open interest of just 54 contracts, one of the most extreme new-position signals possible; this is unambiguously Buy-to-Open fresh capital
• 🤝 MID fill — executed at the midpoint of the bid-ask spread, the hallmark of institutional block negotiation; a retail order would have paid the ask
• 🎯 Breakeven at expiration: $76.60 ($70 strike + $6.60 premium paid) = needs a +24.7% rally from current levels

What's the thesis here?

This is a high-conviction institutional bet that Boston Scientific has 11 months of fundamental runway to push materially higher. At $6.60 per share (~10.7% of spot), they're buying leveraged exposure to a company that has consistently beaten estimates and raised guidance. The $70 strike — which lines up with a significant gamma concentration zone per the GEX data — is not a casual target. It sits at the upper end of what the implied move distribution considers achievable by the March 2027 LEAPS expiration. The trader is not betting on a moonshot; they're betting on continued medtech leadership and execution.

Why $70? The $70 level carries meaningful gamma weight (4.54B total GEX, second-highest in the structure above spot), making it a natural target zone where dealer hedging flows would amplify upside momentum. Analyst price targets cluster in the $65-$85 range with several above $70, and the options market's own 26% implied move for this expiration sets the upper range at $77.43 — directly encompassing the $70 strike.

---

📈 Technical Setup / Chart Check-Up

YTD Performance

BSX is trading at $61.44 as of April 7, 2026. The medtech sector has navigated a choppy macro environment in early 2026, with tariff uncertainty and broader healthcare policy debates creating intermittent headwinds. Key observations from the price action:

• 📉 Broader market selloff context: April 7 opens in a risk-off environment with macro pressure on equities; BSX's defensive medtech profile has provided relative stability versus high-beta tech names
• 🏥 Medtech resilience: Medical devices tend to hold up better in drawdowns than semiconductors or software — demand for cardiac ablation and LAAC procedures doesn't slow because of tariff anxiety
• 📊 Current range: Price is consolidating in the low $60s; the GEX structure shows tight resistance just overhead at $62 (strongest resistance cluster), with support anchored at $60
• 💪 Institutional accumulation signal: A $1.3M block at the MID in a low-OI contract at 13:10 ET is not a coincidence — this follows the pattern of smart money positioning before an anticipated catalyst or re-rating event

Gamma-Based Support & Resistance Analysis

Current Price: $61.44

The gamma exposure map from the GEX data reveals where options market makers are concentrated, creating natural price magnets, floors, and ceilings:

🔵 Support Levels (Put Gamma Below Price):

• $60 — Strongest support with 3.85B total GEX (2.3% below current price). Net GEX is -2.87B (put-heavy), meaning dealers are long gamma here and will actively buy the dip to hedge. This is the floor. A clean hold of $60 keeps the bullish structure intact.
• $55 — Secondary support with 1.99B total GEX (10.4% below). Meaningful put concentration suggests institutional downside protection already in place at this level.
• $50 — Deep structural support with 0.47B total GEX (18.6% below). A significant drawdown would be required to reach here; this level would represent a fundamental breakdown.

🟠 Resistance Levels (Call Gamma Above Price):

• $62 — First and strongest immediate resistance with 2.96B total GEX (just 1% overhead). Net GEX is nearly flat (+0.02B), meaning both calls and puts are concentrated here — dealers will suppress volatility around $62 in the near term. Breaking $62 cleanly is the first technical hurdle.
• $63 — Second resistance at 1.27B total GEX (2.6% overhead). Clearing $62 likely opens a quick path to $63.
• $64 — Third resistance with 2.59B total GEX (4.2% overhead). Net GEX is strongly positive (+2.52B, call-dominated) — dealers are short gamma here and will need to buy stock to hedge as price approaches, which can accelerate moves through this level.
• $65 — Major gamma concentration at 8.99B total GEX (5.9% overhead) — this is the biggest gamma node above spot. Mixed net GEX (-2.86B) signals both heavy call and put positioning, creating a magnet effect. Breaking and holding $65 would be a significant technical achievement.
• $67 — Secondary resistance at 0.91B total GEX (9.1% overhead).
• $70 — The call strike in this trade: 4.54B total GEX (14.0% overhead), net GEX -0.30B (nearly balanced). This is a significant gamma concentration — reaching $70 triggers accelerated hedging flows that could create momentum through the level.
• $72.50 — Extended resistance at 1.25B total GEX (18.1% overhead). Net GEX +0.86B (call-dominated), so dealers would actually buy stock to hedge as price approaches here.

What this means for the $70 call trade:

BSX faces a stacked series of resistance levels between $62 and $70. The $65 node is the key battleground — if the stock can absorb and break through $65, the path to $67-$70 opens considerably. The $70 gamma concentration means that if BSX approaches that level, dealer hedging activity could create a self-reinforcing push higher. This is precisely where a LEAPS holder wants the stock to be headed.

Net GEX Bias: Bullish — Total call GEX (20.99B) slightly exceeds total put GEX (19.75B), meaning the aggregate market maker positioning leans marginally toward the upside. The dealer book is not net bearish on BSX.

Implied Move Analysis

Options market pricing for upcoming expirations (from implied move data):

• 📅 Weekly (Apr 10 — 3 days): ±$1.70 (±2.77%) → Range: $59.75 — $63.15
• 📅 Monthly OPEX (Apr 17 — 10 days): ±$2.59 (±4.22%) → Range: $58.86 — $64.04
• 📅 May 2026 OPEX (May 15): Upper $65.39 / Lower $57.51
• 📅 June 2026 Triple Witch (Jun 19): Upper $66.71 / Lower $56.19
• 📅 July 2026 OPEX (Jul 17): Upper $68.03 / Lower $54.87
• 📅 August 2026 OPEX (Aug 21): Upper $69.34 / Lower $53.56
• 📅 September 2026 Triple Witch (Sep 18): Upper $70.22 / Lower $52.68
• 📅 October 2026 OPEX (Oct 16): Upper $71.53 / Lower $51.37
• 📅 November 2026 OPEX (Nov 20): Upper $72.85 / Lower $50.05
• 📅 December 2026 Triple Witch (Dec 18): Upper $74.16 / Lower $48.74
• 📅 LEAPS Expiration (Mar 2027 — THIS TRADE!): ±$15.98 (±26.0%) → Upper $77.43 / Lower $45.47

Translation for this trade:

The options market's own implied move for the March 2027 LEAPS expiration puts the upper range at $77.43 — which means the $70 call strike is well within the expected distribution. The market assigns meaningful probability to BSX reaching $70+ over the next 11 months. Crucially, the implied move data shows the $70 level is crossed by the upper bound of the expected range as early as the August-September 2026 OPEX timeframe — giving this LEAPS buyer multiple inflection windows where they could be profitable on a mid-trade exit, even before the March 2027 expiration.

Key insight: At 26% implied move for the LEAPS expiration, the market is pricing in substantial uncertainty — but the $70 strike sits comfortably inside the upper half of that distribution. This trader is not making a lottery bet; they're positioning for a scenario the market itself considers achievable.

---

🎪 Catalysts

🔥 Upcoming Catalysts

Q1 2026 Earnings — Expected Late April / Early May 2026 📊

This is the first major checkpoint. BSX has been one of the most consistent earnings beats in the S&P 500 healthcare sector, driven by its FARAPULSE and WATCHMAN platforms. Key items to watch:

• 📊 FARAPULSE (pulsed field ablation) revenue trajectory — the fastest-growing product in BSX's history
• 🫀 WATCHMAN FLX LAAC adoption rates globally; international expansion is still in early innings
• 🌍 Impact of tariff/trade policy on supply chain costs (BSX manufactures across Ireland, US, and other jurisdictions)
• 📈 Full-year guidance — any raise would be a catalyst; BSX has a track record of conservative guidance followed by beats
• 💡 Updates on EP Navigator and next-generation mapping system integrations

EP (Electrophysiology) Market Expansion 🔬

Pulsed field ablation is reshaping how atrial fibrillation is treated globally. BSX's FARAPULSE holds a first-mover advantage in PFA:

• 🏥 PFA adoption is still early in Europe and just beginning its US ramp — the total addressable market is hundreds of thousands of procedures annually
• ⚡ FARAPULSE has demonstrated superior safety profiles vs. thermal ablation (RF and cryo), driving rapid physician uptake
• 📈 Analysts estimate FARAPULSE could reach $1.5-2B+ in annual revenue at full penetration — a significant contribution to a company generating ~$16-17B in annual revenue

WATCHMAN FLX Platform — Structural Heart Tailwind 🫀

Left atrial appendage closure is the only non-pharmaceutical stroke prevention option for afib patients who cannot tolerate long-term anticoagulants:

• 📊 WATCHMAN is the dominant commercial product in a growing LAAC market
• 🌍 International expansion — particularly Japan and emerging markets — represents multi-year runway
• 💡 Next-generation WATCHMAN EZ (simplified implant procedure) could accelerate physician adoption by reducing procedure complexity

FDA Pipeline & Approvals — Multiple Shots on Goal 🎯

BSX has a broad regulatory pipeline across divisions:

• 🩺 Neuromodulation: FAST ECS spinal cord stimulation system, next-gen Vercise DBS for Parkinson's disease
• 🔬 Endoscopy: AI-assisted colonoscopy detection systems and single-use endoscopy expansion
• 🫁 Interventional Cardiology: Next-generation SENTINEL cerebral embolic protection and Acurate structural heart valve iterations
• 💊 Urology & Pelvic Health: Continued Rezum water vapor therapy expansion and InterStim micro sacral neuromodulation growth

International Market Penetration 🌍

BSX generates approximately 40-45% of revenue outside the US. Key growth vectors:

• 🇪🇺 Europe: PFA adoption ramping as FARAPULSE gains deeper hospital penetration post-initial launch
• 🇨🇳 China: Volume-based procurement (VBP) creates pricing pressure but BSX's premium EP portfolio is less exposed than commodity device categories
• 🌏 Japan & Emerging Markets: WATCHMAN FLX approvals and FARAPULSE launches represent medium-term catalysts

Q2 2026 Earnings — Expected Late July 2026 📊

• Full-quarter contribution from FARAPULSE US ramp should be visible
• Updated full-year guidance following Q1 print
• Any updates on pending FDA submissions

JPMorgan Healthcare Conference / Medical Society Events 🎤

BSX is a regular presenter at major healthcare investment and medical society conferences (Heart Rhythm Society, Transcatheter Cardiovascular Therapeutics). These events often serve as venues for clinical data releases that move the stock.

✅ Recent Catalysts (Already Happened)

Q4 2025 Earnings — January/February 2026 📊

BSX has consistently delivered strong results — double-digit organic revenue growth is now the expectation, not the surprise. The medtech growth flywheel (FARAPULSE + WATCHMAN + endoscopy + neuromodulation) has been compounding for several quarters.

FARAPULSE US Commercial Expansion — 2025-2026 🔬

FDA approval and US commercial launch of pulsed field ablation has been BSX's most consequential product launch in a decade. The clinical community's reception has been enthusiastic, with leading EP centers adopting the technology rapidly.

Strategic M&A Activity 🤝

BSX has been an active acquirer, supplementing organic growth with bolt-on deals in high-growth adjacencies. Management has demonstrated disciplined capital allocation — acquisitions at BSX have generally been earnings-accretive within 2-3 years.

---

🎲 Price Targets & Probabilities

Using gamma levels, implied move data, the LEAPS expiration structure, and the fundamental catalyst calendar, here are the scenarios through the March 19, 2027 expiration:

📈 Bull Case (30% probability)

Target: $75-$85

How we get there:

• 🚀 FARAPULSE exceeds $1B in 2026 revenue, driving meaningful upward revisions to BSX's top-line estimates
• 💪 Two-to-three consecutive earnings beats with guide-raises through Q1 and Q2 2026
• 🏥 WATCHMAN FLX gains international traction, expanding the LAAC market faster than expected
• 🎯 Multiple FDA approvals from pipeline submissions — each is an incremental positive catalyst
• 📈 Stock breaks through the $65 gamma node (major resistance), triggering dealer hedging momentum through $67 toward $70
• 🤝 Potential strategic partnership or significant international distribution agreement
• 💡 Analyst upgrades pushing consensus price targets into the $80-$90 range

Call trade P&L at $77.43 (implied upper bound): Calls worth ~$7.43/share, near breakeven on intrinsic, plus residual time value — recovering most of initial premium Call trade P&L at $80: Calls worth $10/share vs $6.60 paid, profit = $3.40/share x 2,000 contracts = $680,000 gain (51% ROI) Call trade P&L at $85: Calls worth $15/share, profit = $8.40 x 2,000 contracts = $1.68M gain (127% ROI)

In the bull case, BSX re-rates toward the upper end of analyst estimates, rewarding a LEAPS holder handsomely. The long runway to March 2027 is the key — this buyer has time to be right even if the path is non-linear.

🎯 Base Case (45% probability)

Target: $65-$75

Most likely scenario:

• ✅ FARAPULSE continues its adoption curve, contributing meaningful revenue but below the most aggressive forecasts
• 📊 BSX delivers steady double-digit organic growth (10-12% range) but without a transformative beat
• ⚖️ Stock grinds through resistance at $62, $63, $64, and battles the $65 gamma node over several months
• 🔄 Multiple re-tests of support at $60 during macro-driven risk-off episodes keep the path choppy
• 📈 Stock is in the $68-$73 range by year-end 2026, creating significant optionality for the March 2027 LEAPS

Call trade P&L at $70 (at strike, March 2027): Deep OTM premium collapsed to near zero, loss = -$1.32M (-100%) Call trade P&L at $73: Calls worth $3/share, partial recovery = -$720K (-55% loss) — but mid-trade exit near $70 in Q4 2026 with time value could recover significantly more Call trade P&L at $75: Calls worth ~$5/share, near breakeven territory — -$320K loss (-24%)

Key nuance: In the base case, this trade's outcome hinges heavily on when BSX reaches $68-$70. If BSX touches $68-$70 in Q3-Q4 2026, the remaining time value (4-6 months) on the LEAPS means the position could trade at or near intrinsic + meaningful time value — a profitable mid-trade exit even if the stock retreats before March 2027.

📉 Bear Case (25% probability)

Target: $52-$60

What could go wrong:

• 😰 FARAPULSE adoption stalls — competitive responses from Abbott's Volt PFA system or Medtronic entries slow BSX's market share gains
• 🚨 Tariff-driven manufacturing cost increases compress gross margins and force a guidance cut
• 📉 Broader healthcare sector de-rating from policy risk (drug pricing negotiations extend to device pricing, CMS reimbursement cuts)
• 💸 A large acquisition at premium valuation dilutes near-term EPS and disappoints the market
• 🏥 An adverse clinical data readout in a major BSX pipeline program (safety signal, regulatory setback)
• 📊 Break below $60 gamma support triggers cascade toward $55 and deeper
• 🌍 China VBP expansion into EP/cardiology product categories hits BSX revenue significantly

Call trade P&L: Calls expire worthless if BSX is below $70 at March 2027 OPEX — loss = -$1.32M (-100%)

The $60 gamma support level is the critical line. If BSX holds $60 consistently, the LEAPS has a viable path. A decisive break below $60 with the stock retreating toward $55 would require a very sharp recovery to recover value from this position.

---

💡 Trading Ideas

🛡️ Conservative: "Follow the Smart Money Cheaper" — Bull Call Spread

Play: Buy the BSX March 2027 $62.50 calls, sell the March 2027 $70 calls

Structure: $62.50/$70 bull call spread, same expiration as the institutional trade

Why this works:

• 📊 Captures the same directional thesis but at dramatically lower cost — likely $3.50-$4.50 net debit vs $6.60 for the outright call
• 🛡️ Defined risk: maximum loss is the net debit paid, no surprises
• 💰 Max profit: $7.50 per spread minus debit (~$3.00-$4.00 gain) if BSX is above $70 at expiry — roughly 70-100% return on capital deployed
• ⏰ Same 11-month runway captures all major catalysts
• 📈 The $62.50 long strike is much closer to at-the-money, meaning higher delta and faster response to stock moves
• 🎯 The $70 short strike perfectly mirrors the institutional conviction level — you're selling against the exact target the whale is betting on

Position sizing: Risk 2-4% of portfolio. 20 spreads at ~$4 each = ~$8,000 risk for ~$15,000 max profit.

Risk level: Low-Moderate (defined risk, directional) | Skill level: Intermediate

⚖️ Balanced: "Gamma Surfer" — June/July Bull Call Spread

Play: Buy BSX June 2026 $62 calls, sell BSX June 2026 $65 calls

Why this works:

• 🎯 Targets the near-term path to the first major gamma resistance at $65 — a meaningful but achievable milestone over 2-3 months
• 💸 Much cheaper than LEAPS — likely $1.00-$1.75 net debit for a $3.00 wide spread
• 📊 Risk/reward of roughly 2:1 if BSX clears $65 by June OPEX
• ⏰ Captures the Q1 earnings catalyst (May) and any subsequent guidance raise reaction
• 📈 If BSX breaks $65 cleanly, this spread pays max at expiration while also creating a base to roll into longer-dated positions

Position sizing: 30-50 spreads at ~$1.50 each = $4,500-$7,500 risk for $9,000-$15,000 max profit.

Risk level: Moderate (near-term defined risk, needs price follow-through) | Skill level: Intermediate

🚀 Aggressive: "Mirror the Whale" — Mar 2027 $70 Calls Outright

Play: Buy BSX March 2027 $70 calls outright — the exact same contract

Why this works (and why it's risky):

• 💥 Pure directional exposure with the same 11-month runway — if BSX rallies hard, gains are uncapped
• 📊 Vol/OI ratio of 37x is an extraordinary signal — this is fresh institutional conviction with no offsetting context suggesting it's a hedge
• ⏰ The March 2027 expiration captures 3 full earnings cycles, multiple FDA decisions, and the full FARAPULSE growth curve
• 🚀 If BSX reaches $80 by March 2027, these calls would be worth ~$10+, a 50%+ gain on a $6.60 entry
• 📈 Mid-trade exits are viable: if BSX reaches $68-$70 by September/October 2026, remaining time value keeps the contract worth $4-6+ even before expiration

Why it could go wrong:

• 💸 $6.60 per contract ($660 per contract, $66,000 for 100 contracts) — not cheap in absolute terms
• ⏰ Every day without progress, theta (time decay) is working against you — approximately $0.01-$0.015/day per contract early on, accelerating toward expiration
• 📉 BSX needs to be above $76.60 at expiration to profit — that's a 24.7% rally from today
• 🎢 If BSX stays in the $60-$65 range through 2026, these calls could lose 70-80% of value well before expiration

Position sizing: Risk only what you can lose in full. 10 contracts = ~$6,600 at risk. Never size this as more than 3-5% of portfolio.

Risk level: HIGH (can lose 100% of premium) | Skill level: Advanced

---

⚠️ Risk Factors

Key landmines to watch:

• 📉 Strike is 13.9% OTM with breakeven at +24.7%: While more conservative than many LEAPS bets, BSX still needs to clear $62, $63, $64, $65, $67, and $70 — five distinct resistance levels — to reach the strike. Gamma compression near $62 may cause the stock to "pin" around that level for extended periods near near-term OPEX dates, eating time value.

• ⚔️ Competitive dynamics in PFA are intensifying: Abbott Medical's Volt PFA system received CE Mark approval and is pursuing FDA clearance. Medtronic and other players are developing competing pulsed field ablation platforms. If competitors close the performance or usability gap, FARAPULSE's pricing power and market share trajectory could moderate.

• 🏥 Healthcare policy and reimbursement risk: Any CMS announcements around cardiac ablation reimbursement rates, or broader policy moves affecting the medical device industry (e.g., device excise tax re-implementation, sequestration), can create immediate negative reactions even without fundamental impact.

• 🌍 Tariff and trade policy uncertainty: BSX manufactures across multiple international sites. A meaningful tariff regime on imported medical devices or components could pressure gross margins and force a guidance revision, a negative catalyst for a stock trading at a premium valuation.

• 💸 Premium valuation demands flawless execution: BSX typically trades at 30-40x forward earnings, reflecting its growth profile. Any earnings miss or guidance cut at this multiple compresses sharply. One bad quarter can erase months of multiple expansion.

• 📊 Low OI before this trade (54 contracts): The $70 March 2027 strike was not a heavily trafficked contract before today. While the 37x Vol/OI ratio is a strongly bullish signal, the limited prior positioning means there is no existing "wall" of call open interest creating upward gamma pressure at $70. The institutional buyer is building that position — it doesn't exist yet.

• ⏰ Time decay accelerates in the back half: LEAPS bleed premium slowly in the first 6 months but theta begins accelerating materially once you pass the 180-day mark. If BSX hasn't made meaningful progress toward $65+ by Q3 2026, the position starts decaying faster as the March 2027 expiration approaches.

• 🎢 Vol crush risk: If broader market implied volatility compresses significantly (a "vol crush" event like a trade deal or major risk-on catalyst), BSX's 26% implied move LEAPS contracts could lose value even if the stock is unchanged or slightly higher — vega exposure works both ways.

---

🎯 The Bottom Line

Here's the deal: An institution just committed $1.3 million to a BSX March 2027 $70 call, buying 2,000 contracts into a strike that had virtually no open interest (just 54 contracts). The 37x Vol/OI ratio is as clean a "new money, new position" signal as the tape produces. This is not a hedge, not a roll — it is a directional conviction bet that Boston Scientific will trade meaningfully higher over the next 11 months.

What this trade tells us:

• 🎯 Institutional money sees BSX clearing $70 — or at minimum getting close enough for mid-trade profitability — by March 2026 OPEX
• 💰 The buyer is paying roughly 10.7% of spot for 11 months of leveraged upside in a medtech leader with durable fundamentals
• ⏰ The March 2027 LEAPS expiration is strategic: it captures 3 full earnings cycles, the full 2026 FARAPULSE ramp, multiple FDA decision windows, and major medical society conference seasons
• 📊 The 37x Vol/OI is not noise — at 2,000 contracts vs 54 OI, this is institutional size entering a previously quiet contract with purpose

This IS a bullish signal — with clear context: The $70 strike is achievable by the implied move framework (upper range $77.43), not a fantasy. The path runs through meaningful gamma resistance at $62, $65, and $67, which means the stock will face friction on the way up. The buyer has time — 11 months — to navigate those levels. If BSX's fundamentals continue compounding (FARAPULSE adoption, WATCHMAN growth, margin expansion), the stock has the earnings power to push through those resistance zones organically.

If you're bullish on BSX:

• ✅ Consider defined-risk bull call spreads ($62.50/$70 for March 2027) to participate in the same thesis at lower cost with capped risk
• 📊 The $60 gamma support is your near-term floor — set alerts if the stock breaks and holds below $60 with volume
• ⏰ Mark the Q1 2026 earnings date (likely late April) as your first major thesis checkpoint
• 💡 Watch for FARAPULSE revenue commentary in each quarter — it's the single most important fundamental variable driving institutional sentiment on BSX

If you're watching from the sidelines:

• 🎯 The current $61.44 price sits in a tight gamma range ($60 support, $62 resistance). A clean break above $62 with sustained buying would be a constructive technical signal to enter
• 📊 Wait for Q1 earnings confirmation of the growth trajectory before committing to longer-dated exposure
• 📈 Analyst price targets above $70 suggest the Street already sees the pathway — the question is timing and catalyst sequencing

If you're cautious:

• ⚠️ The breakeven at $76.60 is a high bar — even for a best-in-class medtech company, a 24.7% rally from current levels in 11 months requires multiple things to go right (earnings beats, no sector selloffs, no competitive surprises)
• 📉 A decisive break below $60 gamma support would damage the near-term technical picture and signal that $55 support is next in line
• 🛡️ If holding long BSX stock, consider a collar (sell the $67.50-$70 calls, buy the $57.50-$60 puts) to lock in gains while funding downside protection

Key dates to mark:

• 📅 Late April / Early May 2026 — Q1 2026 earnings (FARAPULSE revenue + full-year guidance)
• 📅 May 2026 — Heart Rhythm Society Annual Scientific Sessions (key FARAPULSE clinical data forum)
• 📅 Late July 2026 — Q2 2026 earnings (first full 2-quarter view of 2026 growth trajectory)
• 📅 September 2026 — Triple Witch OPEX — implied upper range reaches $70.22, creating mid-trade optionality
• 📅 Late October 2026 — Q3 2026 earnings (make-or-break for annual guidance achievement)
• 📅 November / December 2026 — Analyst days, TCT conference — potential catalyst for target raises
• 📅 March 19, 2027 — THIS TRADE EXPIRES — moment of truth for the $1.3M conviction bet

Final verdict: Boston Scientific is the kind of company institutions build multi-year LEAPS positions on. The FARAPULSE and WATCHMAN platforms represent durable, compounding growth drivers in large, underpenetrated global markets. The $1.3M bet into a virtually empty contract at a 37x Vol/OI ratio suggests someone with deep research has made a decision — not a speculation. The smarter retail approach is to use defined-risk call spreads that participate in the upside while eliminating the tail risk of paying $6.60 in full premium. Let the institutions carry the conviction; you ride alongside with controlled exposure.

Be patient. FARAPULSE's adoption curve is measured in years, not quarters. And remember: $6.60 per share in LEAPS premium means the buyer needs BSX above $76.60 to profit at expiration — but with 11 months of time value, a move to $70 by September/October 2026 could still be a winning mid-trade exit. 💪

Disclaimer: Options trading involves substantial risk of loss and is not suitable for all investors. This analysis is for educational purposes only and does not constitute financial advice. Past performance does not guarantee future results. LEAPS calls are high-risk instruments that can lose 100% of premium paid if the underlying stock does not reach the strike by expiration. Always conduct your own research and consider consulting a licensed financial advisor before making any investment decisions.

---

About Boston Scientific: Boston Scientific is a leading global developer, manufacturer, and marketer of minimally-invasive medical devices across cardiovascular, rhythm management, endoscopy, neuromodulation, and urology markets, with a market cap of approximately $90B.